A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model

Nanobody; an Old Concept and New Vehicle for Immunotargeting

(2011) Fatemeh Rahbarizadeh et al.   IMMUNOLOGICAL INVESTIGATIONS

Characterization of Botulinum Neurotoxin Type A Neutralizing Monoclonal Antibodies and Influence of Their Half-Lives on Therapeutic Activity

(2010) Christelle Mazuet et al.   PLoS One

Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases

(2010) Jacqueline M. Tremblay et al.   TOXICON

Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease

(2010) Lisa M. Eubanks et al.   ACS Medicinal Chemistry Letters

Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents

(2009) J. Sepulveda et al.   INFECTION AND IMMUNITY

Antibody Protection against Botulinum Neurotoxin Intoxication in Mice

(2009) L. W. Cheng et al.   INFECTION AND IMMUNITY

Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3

(2009) Robert P. Webb et al.   VACCINE

General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold

(2008) Cécile Vincke et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Neutralization of Botulinum Neurotoxin by a Human Monoclonal Antibody Specific for the Catalytic Light Chain

(2008) Sharad P. Adekar et al.   PLoS One

Single-domain antibody fragments with high conformational stability

(2002) Mireille Dumoulin et al.   PROTEIN SCIENCE